Cerebral ischaemia and matrix metalloproteinase-9 modulate the angiogenic function of early and late outgrowth endothelial progenitor cells by Morancho, Anna et al.
Cerebral ischaemia and matrix metalloproteinase-9 modulate the
angiogenic function of early and late outgrowth endothelial
progenitor cells
Anna Morancho a, Mar Hernandez-Guillamon a, Cristina Boada a, Veronica Barcelo a, Dolors Giralt a,
Laura Ortega a, Joan Montaner a, Anna Rosell a, *
a Neurovascular Research Laboratory, Vall d’Hebron Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain
Received: March 20, 2013; Accepted: July 17, 2013
Abstract
The enhancement of endogenous angiogenesis after stroke will be critical in neurorepair therapies where endothelial progenitor cells (EPCs)
might be key players. Our aim was to determine the influence of cerebral ischaemia and the role of matrix metalloproteinase-9 (MMP-9) on the
angiogenic function of EPCs. Permanent focal cerebral ischaemia was induced by middle cerebral artery (MCA) occlusion in MMP-9/knockout
(MMP-9/KO) and wild-type (WT) mice. EPCs were obtained for cell counting after ischaemia (6 and 24 hrs) and in control animals. MatrigelTM
assays and time-lapse imaging were conducted to monitor angiogenic function of WT and MMP9-deficient EPCs or after treatment with MMP-9
inhibitors. Focal cerebral ischaemia increased the number of early EPCs, while MMP-9 deficiency decreased their number in non-ischaemic
mice and delayed their release after ischaemia. Late outgrowth endothelial cells (OECs) from ischaemic mice shaped more vessel structures
than controls, while MMP-9 deficiency reduced the angiogenic abilities of OECs to form vascular networks, in vitro. Treatment with the MMP
inhibitor GM6001 and the specific MMP-9 inhibitor I also decreased the number of vessel structures shaped by both human and mouse WT
OECs, while exogenous MMP-9 could not revert the impaired angiogenic function in MMP-9/KO OECs. Finally, time-lapse imaging showed that
the extension of vascular networks was influenced by cerebral ischaemia and MMP-9 deficiency early during the vascular network formation fol-
lowed by a dynamic vessel remodelling. We conclude that focal cerebral ischaemia triggers the angiogenic responses of EPCs, while MMP-9
plays a key role in the formation of vascular networks by EPCs.
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Introduction
Stroke is a major cause of morbidity and mortality worldwide, but the
only available treatments are reperfusion therapies using tissue plas-
minogen activator or clot retrieval interventions in certain patients
with acute ischaemic strokes. However, only 2–5% of stroke patients
are receiving thrombolytic therapy to restore the blood flow [1] and
the impact of clot retrieval interventions is still under evaluation. In
this context, as important as neuroprotection therapies, it is the
enhancement of endogen neuroreparative responses that contributes
to stroke recovery [2]. It has been proposed that the activation of
angiogenesis and neurogenesis in the perfused peri-infarct areas
might remodel the damaged frontier tissue leading to behavioural
recovery [3]. For that reason, the enhancement of endogenous angio-
genesis after stroke, which can be activated with cell-based therapies,
is considered to be crucial in future neurorepair strategies.
Angiogenesis is defined as the growth of new blood vessels from
pre-existing vascular structures and EPCs have been shown to partici-
pate in neovascularization in the adult [4]. Circulating EPCs can be
mobilized endogenously in response to ischaemia, home to sites of
neovascularisation and differentiate into endothelial cells, becoming a
new model for endothelial generation and vessel repair [5]. No single
marker exists for this population of progenitor cells and it is accepted
that at least two subsets can be obtained under cell culture: early
EPCs, which appear early in cultures with spindle-shaped morphology
(also named circulating angiogenic cells) and OECs, which appear
later and present clonogenic and tubulogenic potential [6–9]. Several
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studies using in vitro and in vivo models have demonstrated the role
of EPCs as a pro-angiogenic cell-based treatment in hindlimb or cere-
bral ischaemia [10–13]. The factors influencing EPCs function are still
being identified and under investigation as their modulation might
improve future cell-based therapies.
During new vessel formation, one of the earliest steps is the deg-
radation of the basal membrane, and MMPs are key players that could
determine the success of this complex process [14]. Among them,
the gelatinase MMP-9 has been shown to be essential for capillary
branching, invasion and tube formation of endothelial cells [15, 16].
Additionally, MMP-9 has been shown to play a dual role after ischae-
mia, their up-regulation being detrimental in the acute phases, but
becoming essential for an effective neurorepair [17–21].
Our hypothesis is that cerebral ischaemia is a trigger for EPC release
and functions, while MMP-9 deficiency reduces EPC levels and impairs
angiogenic function in the context of cerebral ischaemia. For this pur-
pose, EPC cell-culture yields and function were explored in MMP 9-defi-
cient mice compared with WT animals subjected to middle cerebral
artery occlusion. We demonstrate that the angiogenic responses of
EPCs are enhanced by the ischaemic insult and impaired in the absence
of MMP-9. To further test our hypothesis, the function of EPCs from
control subjects was also studied in the presence of two MMP inhibi-
tors, demonstrating the key role of MMPs and MMP-9 in the vasculo-
genic function of EPCs. Time-lapse imaging shows for the first time the
patterns of vessel network formation, which are clearly aberrant in
MMP 9-deficient EPCs and enhanced in ischaemia-stimulated EPCs.
Materials and methods
Animals
Age-matched male mice KO for MMP-9 (MMP-9/KO) and WT mice (strain
background FVB) from Jackson Laboratories (Sacramento, CA, USA) were
used in this study. Matrix metalloproteinase-9 null mice were generated by
replacing part of exon 2 and all intron 2 with a phosphoglycerate kinase-
neomycin cassette as described by Vu et al. [22]. Both mice genotypes
(MMP-9/ and MMP-9+/+) were bred in-house and the offspring was used
for experimentation. Genotyping analysis was performed as detailed in sup-
plemental data. All animals were housed in a temperature-/humidity-con-
trolled room and maintained on a 12-hr light/12-hr dark cycle. Only adult
males (25–35 g bw) were used in the study and free access to food and
water was allowed prior and after surgery. A total of 92 mice were initially
included for the middle cerebral artery occlusion (MCAO) model (ischaemic
and sham animals). All procedures were approved by the local Animal Care
Committee and were conducted in compliance with the Spanish legislation
and in accordance with the Directives of the European Union.
Permanent focal cerebral ischaemia
A reproducible model of stroke by occluding the middle cerebral artery
(MCA) affecting the cortex was induced as previously described (see Sup-
porting Information), [23] Sham animals underwent all surgical proce-
dures with the exception of the MCA occlusion. Six or 24 hrs after the
ischaemia, or after 24 hrs of the surgery in sham group, mice were killed.
Mouse endothelial progenitor cell cultures
Mouse early EPCs were obtained as previously described [24]. Spleens
from WT and MMP-9/KO mice were obtained at 6 or 24 hrs after
ischaemia and in sham animals after 24 hrs. A total of 38 cell cultures
were performed from 76 mice (two spleens each) and images from five
representative fields were taken at 2009 at day 5. EPCs were defined
as spindle-shaped cells at day 5 as previously described and pheno-
typed [24, 25]. Cell counts were performed by an investigator blinded
to the experimental group. Sub-confluent colonies were cultured for fur-
ther expansion; those cells, presenting cobblestone or palisade mor-
phology, are named OECs and were used for in vitro vessel formation
MatrigelTM assays, see Figure S1. Detailed methods are available in Sup-
porting Information.
Human blood EPCs cultures
Human OECs were obtained as previously described from peripheral
blood from healthy controls (aged from 39 to 59) [25]; detailed meth-
ods are available in Supporting Information.
Immunocytochemistry
Standard EPC phenotyping was performed in mouse and human OECs
for von Willebrand factor, KDR and CD133 antigens. Methods are avail-
able in Supporting Information.
In vitro vessel formation
To assess the role of ischaemia and MMP-9 on angio-vasculogenic abili-
ties of OECs, MatrigelTM matrix (BD Biosciences, San Jose, CA, USA) was
used for in vitro vessel formation (also named tubulogenesis). Experi-
mental groups consisted in mouse OECs obtained from ischaemic
(24 hrs) or sham mice, from now on named ischaemic or control OECs,
respectively, or human OECs. Additionally, mouse WT and human cells
were treated with the MMP inhibitor GM6001 (CC100, EMD Millipore,
Darmstadt, Germany) at 10 or 20 lM or the specific MMP-9 inhibitor I
(444278, EMD Millipore) at 100 nM for mouse or 0.5 and 1 lM for
human cells. Finally, MMP-9/KO cells were treated with conditioned media
(CM) obtained from WT OECs or with 20 or 40 nM recombinant mouse
pro-MMP-9 (R&D systems, MN, USA) at 20 or 40 nM. Detailed methods
are available in Supporting Information. The number of complete rings
and the total tube length (perimeter of the complete rings) were counted
by ImageJ software (NIH, Bethesda, MD, USA) by an investigator blinded
to the treatment. Mean values were used for comparisons between cell
types while experimental treatments with MMP inhibitors, CM or recombi-
nant MMP-9 were expressed as percentage of the non-treated group.
Cell viability
Cell viability assay was additionally performed as previously described
[26] to assess the potential toxicity of the MMP inhibitors and their
vehicle media applied to the OECs. Detailed methods are available in
supporting methods.
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Live time-lapse imaging for in vitro vessel
formation
The formation of vessel-like structures by mouse OECs was assessed dur-
ing 24 hrs using time-lapse imaging. Experimental groups were: WT con-
trol, WT ischaemic, MMP-9/KO control and MMP-9/KO ischaemic OECs.
Standard MatrigelTM assay was conducted as described above and image
acquisition started 1 hr after seeding and then every 30 min. up to
24 hrs. An Olympus multi-dimensional-TIRFM cell-R microscope (Olym-
pus, Tokyo, Japan) with temperature, CO2 and humidity control was used.
Two images per well were acquired at 409 and 1009. Complete rings
and branching points (points featuring three or more connections) were
counted every 2 hrs by an investigator blinded to the treatment.
Gelatin zymography
Presence of MMP-9 in CM from WT control and ischaemic cultures was
confirmed as described in the supplemental data.
Brain vasculature quantification
A group of eight WT and eight MMP-9/KO mice were subjected to
permanent focal cerebral ischaemia (n = 4 WT and n = 4 MMP-9/KO)
or sham surgery (n = 4 WT and n = 4 MMP-9/KO). To assess endoge-
nous angiogenesis, after 21 days, mice were injected intravenously with
80 lg of Dylight 594-labelled tomato lectin (Lycopersicon esculentum;
Vector Laboratories, Burlingame, CA, USA) and sacrificed by cardiac
perfusion of 4% paraformaldehyde under deep anaesthesia. Brains were
collected and the lectin positive cortex area analysed. Imaged vessels
presented a diameter smaller than 10 lm typical of microvessel struc-
tures. Detailed methods are available in Supporting Methods.
Statistical analysis
SPSS 15.0 package was used for statistical analyses. Shapiro–Wilk test
was used to verify if variables had a Gaussian distribution. Normally
distributed variables are expressed as mean  SD and represented by
bars, statistical significance for intergroup differences was assessed by
Student’s t-test or ANOVA followed by Tukey post-hoc test. A P < 0.05
was considered statistically significant at a 95% confidence level.
Extreme values were excluded (mean  2SD) (n = 3); this criterion
only affected early EPC counts.
Results
Characterization of MMP 9-deficient mice and
EPCs
Wild-type and MMP-9/KO genotypes were confirmed by PCR
(Fig. S2). A total of 32 mouse EPCs cultures were finally included in
the study after discarding extreme values and contaminated cultures.
Colonies of expanding OECs were obtained in 6 out of 17 cultures
from WT mice (35.3%) and in 2 out of 15 from MMP-9/KO mice
(13.3%) displaying two different morphologies: cobblestone- or pali-
sade- type. No differences were seen regardless of mouse MMP-9
genotype in terms of cell morphology (Fig. 1A and B). Immunopheno-
typing showed that both WT and MMP-9/KO mice and human OECs
were positively stained for endothelial markers (vWF and KDR) and
CD133 progenitor cell marker (Fig. 1C and D) regardless of morphol-
ogy type (see additional immunophenotyping in Fig. S3).
Influence of focal cerebral ischaemia and MMP-9
deficiency on EPC yields
The number of early EPCs as spindle-shaped cells in cultures was
counted (Fig. 2A). Our results showed that in WT mice the number of
EPCs was altered by ischaemia (Fig. 2B, P = 0.055) and although an
increase was detected at 6 hrs this was not significant (P = 0.066)
nor was the change detected at 24 hrs (P = 0.967). Conversely, in
MMP-9/KO mice the ischaemic insult altered the complete temporal
profile (Fig. 2B, P = 0.049) by delaying the peak in the number of
EPCs being significantly higher 24 hrs after ischaemia compared with
sham animals (P = 0.041). Matrix metalloproteinase-9 deficiency
strongly decreased the number of EPCs in sham and 6 hrs ischaemic
mice compared with WT mice (P = 0.012 and P = 0.019, respec-
tively); see Figure 2C. At 24 hrs, WT and MMP-9/KO mice presented a
similar number of EPC yields (P = 0.969) as a consequence of the
delayed increase in EPCs after the ischaemic event in MMP-9/KO mice.
Focal cerebral ischaemia enhances the ability of
WT mouse OECs to form vessel-like structures
determining the maximum extension of vessel-
like networks
Figure 3A shows representative images of vessel-like structures
shaped by OECs of different studied groups. Quantification of Matri-
gelTM assays showed that WT ischaemic OECs were able to shape
more vascular networks than sham OECs. Ischaemic cells obtained
from WT mice completed a higher number of rings (P = 0.007) and
shaped larger networks (P = 0.002) than control cells. In contrast, in
MMP-9/KO cells the ischaemic insult only increased the number of
rings (P = 0.031), but had no effect on the network length
(P = 0.313); see Figure 3B and C.
Time-lapse imaging revealed that generation of vessel-like struc-
tures into a MatrigelTM matrix began only 2 hrs after seeding, while
the maximum number of vessel-like structures was shaped approxi-
mately at 10 hrs as shown in Figure 3D and E and Figure S4. Inter-
estingly, the construction period was followed by a dynamic
remodelling seen only in the supporting video files of time-lapse
imaging (Videos S1–S4). Table 1 shows significant differences on
vessel network formation during the established construction period
versus the remodelling period. Time-lapse imaging results confirmed
that angiogenic abilities of OECs are strongly enhanced in WT ischae-
mic cells (P < 0.05 versus WT control cells). However, in a context of
ª 2013 The Authors.
Journal of Cellular and Molecular Medicine Published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1545
J. Cell. Mol. Med. Vol 17, No 12, 2013
MMP-9 deficiency, ischaemic cells were not superior to control cells
showing the importance of MMP-9 for angiogenic responses of EPCs
(Fig. 3D and E, Figure S4 and Videos S1–S4).
MMP-9 deficiency impairs the formation of
vessel-like structures by mouse OECs
Control cells with MMP-9/KO genotype showed reduced angiogenic
abilities when compared with WT cells as demonstrated by less rings
and shorter total tube length shaped by MMP-9/KO control OECs in
MatrigelTM assays (P = 0.001 and P = 0.001, respectively); see Fig-
ure 4A. Time-lapse imaging confirmed the influence of MMP-9 defi-
ciency in the vessel network formation over time (Fig. 4B). The video
images (Videos S1 and S3) also illustrate differences in the patterns
of movement, showing that WT OECs can move much faster and make
more cell-to-cell connections than MMP-9/KO OECs, which show clear
impaired function. The same experimental groups were tested using
ischaemic cells as seen in Figure 4C. Ischaemic MMP-9/KO OECs
showed impaired angiogenic function compared with WT ischaemic
cells by forming less rings (P = 0.011) and diminishing total tube
length (P = 0.016). Figure 4D, Figure S4, Videos S2 and S4 show
how the MMP-9 deficiency impairs the vessel network formation over
time also in ischaemic cells, demonstrating the importance of MMP-9
for angiogenic responses of EPCs in the context of ischaemia.
To further confirm the role of MMP-9, WT control cells treated
with the broad spectrum MMP inhibitor GM6001 and the specific
MMP-9 inhibitor I significantly reduced their angiogenic abilities by
decreasing the number of rings compared to non-treated cells
(P < 0.001 and P = 0.04, respectively) and the total tube length
(P < 0.001 and P = 0.054, respectively); see Figure 5A. The addition
of exogenous MMP-9 by adding CM from WT OECs containing MMP-
9 (Fig. S5), 20 or 40 nM of recombinant pro-MMP-9 could not revert
the ability to form vessel-like structures of MMP-9/KO cells (P > 0.05
for ring structures and total tube length for all experimental condi-
tions) as shown in Figure 5B. In addition, the treatment of ischaemic
WT OECs with GM6001 and MMP-9 inhibitor I also reduced the
angiogenic performance of ischaemic OECs, showing less number of
rings (P = 0.007 and P = 0.044, respectively) and diminished total
tube length (P = 0.005 and P = 0.044) than non-treated cells
(Fig. 5C). In MMP-9/KO ischaemic OECs, the addition of CM from WT
OECs did not improve significantly the formation of vessel-like struc-
tures as shown in Figure 5D (P = 0.579 for number of rings and
P = 0.253 for total tube length).
Any of theMMP inhibitor treatments or their vehicles affected the cell
viability ofWT control or ischaemic OECs as shown in Figure S6A and B.
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Fig. 1 Immunophenotypic characteristics of outgrowth endothelial cells (OECs) from wild-type (WT) and matrix metalloproteinase-9/knockout (MMP-
9/KO) mice and human controls. (A) Representative images of OECs from WT and MMP-9/KO obtained from ischaemic mice showing cobblestone
or palisade cell morphologies (bar = 100 lm). (B) Representative micrographies from human OECs. Immunofluorescent staining of OECs showing
positive signal (red or green) for von Willebrand factor (vWF), KDR and CD133 (bar = 50 lm) in mouse palisade-type (C) and human cobblestone-
type cells (D). The blue signal corresponds to nuclear DAPI.
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Inhibition of MMPs reduces the angiogenic
capacity of human OECs
Human OECs with cobblestone morphology were used in the tubulo-
genic assays. When treating OECs from control animals with 10 lM
of GM6001, we could not observe reduced angiogenesis as seen in
Figure 5F. Doubling the concentration of GM6001 to 20 lM led to a
significant decrease in OECs angiogenic function by reducing both the
number of vessel structures (P < 0.001) and total tube length
(P < 0.001) compared with non-treated OECs; see Figure 5E and F.
The specific role of MMP-9 was also demonstrated as treatment with
0.5 and 1 lM of MMP-9 inhibitor I also decreased the number of
rings (P < 0.001 and P < 0.001, respectively) and the total tube
length (P < 0.001 and P < 0.001, respectively).
None of the tested doses of GM6001 or MMP-9 inhibitor I and
none of their vehicles showed any effect on cell viability; see
Figure S6C.
In vivo angiogenesis after focal cerebral
ischaemia is impaired in MMP 9-deficient mice
In a pilot study, we explored how MMP-9 deficiency could affect
endogenous angio-vasculogenesis in the context of cerebral ischae-
mia. When comparing the amount of functionally perfused blood mi-
crovessels (as stained by lectin intravenous perfusion) in the peri-
infarct cortex between control and ischaemic animals, WT mice
showed an increase in the vessel density 21 days after ischaemia in
some areas of the cortex affected for the infarct (P = 0.026 for pos-
terior areas). However, in MMP-9/KO mice, there was no increase in
the vessel density after the ischaemic insult in any of the studied
areas (P > 0.05); see Figure S7.
Discussion
Our study shows that focal cerebral ischaemia promotes an acute
mobilization of EPCs, while MMP-9 deficiency decreases the number
of circulating EPCs delaying their mobilization after an ischaemic
insult. We also demonstrate that focal cerebral ischaemia enhances
the angiogenic abilities of late outgrowth EPCs in vitro, being partially
impaired in MMP 9-deficient cells. Finally, the pharmacological inhibi-
tion of MMPs, specifically MMP-9, impaired the angiogenic function
of OECs, suggesting that MMP-9 is necessary for de novo vascular
network formation. We also suggest that endogenous angiogenesis in
peri-infarct areas after focal cerebral ischaemia is partly inhibited
in MMP-9/KO mice. All these data proposes MMP-9 as a key protease















































































Fig. 2 Cell density of early endothelial pro-
genitor cells (EPCs). (A) Representative
image of spindle-shaped early EPCs
(arrows); bar = 50 lm. (B) Bars repre-
senting cell density of EPCs from sham
and ischaemic wild-type (WT) or matrix
metalloproteinases-9/knockout (MMP-9/
KO) mice (ANOVA followed Tukey post-hoc
test; *P < 0.05 versus sham). (C) Number
of EPCs at different time-points of ischae-
mia in WT and MMP-9/KO mice. (T-test;
*P < 0.05). Results are expressed as
mean  SD, n = 4–6/group.
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Two different types of EPCs have been described and identified in
culture, early EPCs and late OECs, which present differences in phe-
notype, proliferation capacity and function [7]. Recruitment and
mobilization of EPCs play an important role in neovascularization after
tissue injury. Different studies in stroke patients have shown an
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Fig. 3 Effect of ischaemia on MatrigelTM assay performance of mouse outgrowth endothelial cells (OECs). (A) Representative micrographs of vessel-
like structures shaped by control and ischaemic (24 hrs) wild-type (WT) and matrix metalloproteinases-9/knockout (MMP-9/KO) OECs (bar = 50 lm).
The number of rings and total length of vessel-like structures of control and ischaemic OECs was quantified for WT (B) and MMP-9/KO cells (C).
Quantification of time-lapse imaging assay of mouse OECs on MatrigelTM matrix shows the effect of ischaemia on WT (D) and MMP-9/KO (E) on the
formation and dynamics of vessel-like structures in each experimental group. Two clear patterns were observed in all groups highlighted as construc-
tion or remodelling. Results are expressed as mean  SD; (T-test; *P < 0.05, **P < 0.01 versus control group, n = 3–4 independent experiments).
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insult, while other authors have described lower levels of EPCs in
stroke patients than in controls [25, 27–29]. To evaluate these contra-
dictory data, we aimed, for the first time, to assess the mobilization of
EPCs after an ischaemic insult in a mouse model of stroke. We have
quantified early EPCs in short-term cell cultures from mouse spleens
by counting spindle-shaped cells as previously described by other
authors [24, 25]. The results show an increase in the levels of circu-
lating EPCs early after the ischaemic insult. We have also demon-
strated that MMP-9 deficiency delayed the ischaemia-induced EPC
mobilization. In this sense, it is known that MMP-9 is required for the
mobilization of stem and progenitor cells from the bone marrow [30,
31]. According to these studies, we have observed decreased levels
of early EPCs in MMP-9/KO sham mice compared with WT animals,
confirming an impaired mobilization in MMP 9-deficient animals.
However, as we are considering cultured cells, we have to acknowl-
edge that other factors could be influencing the final counts such as
the cell adherence or survival capacities between WT and MMP-9/KO
EPCs. This result is in agreement with other findings describing
impaired mobilization of bone marrow-derived EPCs in MMP 9-defi-
cient mice [30]. In our study, the ischaemic insult restored the
impaired EPC mobilization of MMP-9/KO sham animals by increasing
EPCs up to the same level as WT mice at 24 hrs. This might suggest
that our model of focal cerebral ischaemia activates other triggers for
bone-marrow cell mobilization in the absence of this protease or com-
pensatory effects by other MMPs explaining the delayed response to
the ischaemic trigger. Our study focuses on the mobilization and
function of EPCs during the acute phase of cerebral ischaemia. How-
ever, the long-term effects and capacity of these cells to modulate
neurorepair in these animal models were not in the scope of the pres-
ent study and will be investigated in future studies.
In the present study, we could obtain late EPCs from spleen
cultures of WT and MMP-9/KO mice, but cultures from MMP 9-
deficient animals yielded a lower percentage of outgrowth cells. In
this regard, other authors have reported reduced colony forming
units of human circulating cells in the presence of an MMP-9
inhibitor [32]. As less cell density was found in MMP-9/KO cul-
tures, we can hypothesize that it could influence the reduced yields
of outgrowth EPCs as described by other authors [33]. Another
explanation could be in the nature of MMP-9 deficiency and
altered mechanisms of EPCs maturation into an endothelial pheno-
type. The identification of the molecular mechanisms leading to
OECs appearance will provide more information of the MMP-9 role
in that process.
Our results demonstrate that the OECs obtained from WT ischae-
mic mice showed enhanced endothelial function by performing higher
number of vessel-like structures than OECs from non-ischaemic
mice. On the other hand, this angiogenic function was only partially
enhanced in ischaemic MMP-9/KO cells, suggesting a mild effect of
the ischaemic trigger on the MMP 9-deficient OECs. The videos sup-
plied as supporting files clearly show the persistent impairment of
MMP-9/KO cells to shape vascular networks despite the ischaemic
trigger. This strongly indicates that focal cerebral ischaemia can
improve angiogenic abilities of OECs and preserve these abilities after
maturation into endothelial-like cells, but this trigger is dependent on
MMP-9 activity. To our knowledge, this is the first work comparing
OECs’ vasculogenic abilities from ischaemic and non-ischaemic ani-
mals in vitro. Supporting our data, a recent investigation has pub-
lished that hypoxia pre-conditioned bone marrow mesenchymal stem
cells (BMSCs) transplanted in rats after cerebral ischaemia improved
the regenerative potential of standard BMSCs, suggesting mecha-
nisms involving enhanced expression and release of trophic/growth
factors [34]. The factors that cerebral ischaemia specifically activates
in circulating EPCs to enhance their angiogenic potential and how the
activation is maintained need to be further studied.
We have shown that MMP-9 deficiency and pharmacological inhi-
bition of MMP-9 clearly impair the angio-vasculogenic abilities of
OECs and that the addition of exogenous MMP-9 could not reverse it,
suggesting that endogenous secreted MMP-9 is essential for a cor-
rect EPC function in terms of de novo vessel formation. We have fur-
ther demonstrated that OECs from MMP-9/KO mice built aberrant
vascular networks compared with WT cells, suggesting a key role of
this MMP in de novo vascular formation. Other authors have shown
similar results when inhibiting MMP-9 in human control OECs [32].
However, we show, for the first time, by time-lapse imaging, the
tube formation patterns over time and specific inability of MMP-9/KO
EPCS for cell migration and for the establishment of cell-to-cell
interactions.
Importantly, we have successfully translated our results into the
human setting. Outgrowth endothelial cells from human controls
diminished their angiogenic abilities and shaped smaller vascular net-
works when treated with the broad spectrum MMP inhibitor or with a
specific MMP-9 inhibitor.




Increase in rings/hour Increase in branching points/hour
0–10 hrs 10–24 hrs P-value 0–10 hrs 10–24 hrs P-value
Control WT 0.64  0.5 0.05  0.5 <0.001 1.12  0.7 0.06  0.7 <0.001
Control MMP-9/KO 0.43  0.5 0.00  0.3 0.005 0.95  1.0 0.00  0.47 0.004
Ischaemic WT 1.48  1.6 0.00  0.9 0.005 3.27  3.1 0.70  0.8 0.001
Ischaemic MMP-9/KO 0.44  0.4 0.10  0.3 0.005 1.24  1.7 0.19  0.4 0.031
Data are given as increase per hour and expressed as mean  SD.
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The function of MMP-9 in vascularization has been previously stud-
ied in other diseases. Johnson and colleagues described in a model of
hindlimb ischaemia that MMP-9 was necessary for ischaemia-induced
angiogenesis as an inhibition of tissue angiogenesis and a decreased
capillary perfusion were found in MMP-9/KO mice [15]. Conversely, in
myocardial infarction, a stimulation of angiogenesis has been
described in MMP-9/KO animals, suggesting a possible dual role of
this MMP depending on the tissue [35]. However, in the brain, MMP-9
seems to be essential for an effective neurorepair [21]. It is well
described that endogenous activation of angiogenesis occurs within
the first hours after cerebral ischaemia [36]. Our results support the
critical role of MMP-9 in spontaneous angiogenesis after cerebral
ischaemia as we have shown an increase in specific peri-infarct vessels
in ischaemic WT mice, but not in MMP-9/KO animals when compared
with non-ischaemic animals. It is important to highlight that with our
perfusion technique of intravenous lectin to stain the blood vessels, we
are only considering functional vessels with normal blood perfusion
excluding any non-functional aberrant vasculature. Whether the
impaired angiogenic function of OECs lacking MMP-9 observed in the
present study could influence neurorecovery needs to be elucidated
and warrants further studies using in vivo models of ischaemia receiv-
ing cellular therapy.
Finally, time-lapse imaging technique performed to examine the
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Fig. 4 Effect of matrix metalloproteinase-9
(MMP-9) deficiency on MatrigelTM assay
performance of mouse outgrowth endothe-
lial cells (OECs). Bar graphs showing in vi-
tro tubulogenesis performance of wild-type
(WT) control compared with MMP-9/
knockout (MMP-9/KO) cells (A) and the
corresponding time-lapse imaging (B) and
WT and the MMP-9/KO ischaemic OECs (C)
and the corresponding time-lapse imaging
(D). Results are expressed as mean  SD.
(T-test; *P < 0.05, **P < 0.01; n = 3–5
independent experiments).
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cerebral ischaemia and MMP-9 determined the extension of the vascu-
lar network. Surprisingly, our results show, for the first time, that the
construction of vessel-like structures in a MatrigelTM matrix by OECs
occurs only during the first hours of the assay, regardless of the pres-
ence or not of MMP-9 or a stimulus such as ischaemia, which could
not accelerate or slow down the establishment of the network. After this
construction phase, the cells were seen in a continuous and dynamic
movement in the remodelling phase maintaining the network extension
in all experimental conditions. We hypothesize that this observation
may respond to the incapacity for stabilization and maturation of newly
formed vessels because of the absence of supporting cells as pericytes
as described [37]. Our results support additional studies to evaluate
if the stability of endothelial cells in more mature vascular structures















































































































































































































































































































































Fig. 5 Effect of matrix metalloproteinases (MMP) inhibition on MatrigelTM assay performance of mouse and human outgrowth endothelial cells
(OECs). (A) Bar graphs showing impaired angiogenic function of wild-type (WT) control cells when treated with GM6001 and MMP-9 inhibitor I
(MMP-9i I). (B) Bar graphs showing that angiogenic performance could not be reverted when MMP-9/knockout (MMP-9/KO) OECs were treated with
exogenous MMP-9 contained in conditioned media (CM) of WT OECs or by recombinant pro-MMP-9 treatment. (C) Bar graphs showing the effect
of pharmacological MMP inhibition of the angiogenic function of WT ischaemic cells. (D) The addition of CM of ischaemic WT OECS could not sig-
nificantly revert the angiogenic impairment of MMP-9/KO ischaemic cells. (E) Representative micrographs of vessel-like structures from human
OECs in the presence or absence of GM6001 and MMP-9 inhibitor I (MMP-9i I); bar = 50 lm. Bar graphs represent number of rings and the total
tube length determined in OECs treated with GM6001 at a final concentration of 10 or 20 lM (F) or treated with 0.5 and 1 lM of MMP-9i-I (G).
Results are expressed as mean  SD and as a percentage of the non-treated group; for different treatments a T-test versus the non-treated control
group was performed in A–D while ANOVA followed by Tukey post-hoc test was performed for dose-response analysis in F and G; *P < 0.05,
**P < 0.01; n = 5–10 independent experiments.
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In summary, the present study demonstrates that focal cerebral
ischaemia triggers the angiogenic responses of EPCs in a mouse
model of stroke. Our findings indicate that MMP-9 deficiency impairs
the mobilization and angiogenic abilities of EPCs, demonstrating that
this protease is necessary for de novo vascular network formation in
the context of ischaemia. We conclude that MMP-9 modulation may
be important for EPC-based therapies to potentiate angiogenesis in the
context of ischaemia. Further in vivo studies are needed to determine
the role of the MMP-9 in angiogenesis in a multiple cell environment
and how this metalloproteinase could be modulated, for example, gen-
erating cells that overexpress this key modulator of EPCs function.
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